Hanmi Pharm "New Drug 'Rolvedon' Achieved $13.1 Million Sales in the US Last Year"

Secured 70 Local Clients in the US

Hanmi Pharm's neutropenia treatment bio new drug 'Rolvedon' recorded sales of over 13 billion KRW in the US market last year.

Spectrum's CI.
[Image provided by Hanmi Pharmaceutical]

Hanmi Pharm announced on the 23rd that its partner Spectrum achieved Rolvedon sales of $10.114 million (approximately 13.1 billion KRW) in the US as of December 31 last year.

Additionally, in the fourth quarter of last year, 70 customers purchased Rolvedon, and it was noted that Rolvedon began to be used in the top three community oncology networks, which account for 22% of the entire clinic market. In December, Rolvedon was included in the febrile neutropenia prevention and treatment option guidelines presented by the National Comprehensive Cancer Network (NCCN) in the US. Recently, Hanmi Pharm anticipated that the inclusion of Rolvedon in the US public insurance reimbursement drug list by the Centers for Medicare & Medicaid Services (CMS) would reduce patients' medical expenses and simplify reimbursement procedures, contributing to its growth.

Spectrum has reduced operating costs by about 45% through management efficiency and plans to continuously invest these savings into core businesses such as Rolvedon sales. Tom Lee, President of Spectrum, said, "We are encouraged by the initial market response to Rolvedon," adding, "We will accelerate future growth by securing appropriate staffing, waste-free infrastructure, and sufficient cash flow."

Rolvedon, developed by Hanmi Pharm and licensed out to Spectrum, received FDA marketing approval in the US in September last year and was launched nationwide in October.

This content was produced with the assistance of AI translation services.